Korro Bio, Inc. (KRRO) Key Metrics

NASDAQ: KRROValuation, returns, debt and efficiency ratios over 9 years.

KRRO valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$125.0M
Enterprise value
$71.8M
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
52.5
10-yr median 81.1
Price / book
1.4
10-yr median 2.1
EV / EBITDA
—
Dividend yield
—
Beta
2.36

KRRO key metrics, 2017–2025

Fiscal year ended December 31, 2025 · U.S. dollars

KRRO valuation Price multiples at each fiscal year-end price.

Price / sales−92.1%
11.8
2025 · hover or tap a bar for each year
2021: 81.12024: 149.52025: 11.8 (−92.1%)
20172025
Price / book−30.9%
1.5
2025 · hover or tap a bar for each year
2021: 8.72024: 2.12025: 1.5 (−30.9%)
20172025
Free cash flow yield−82.1 pts
−105.1%
2025 · hover or tap a bar for each year
2021: −3.2%2024: −23.0%2025: −105.1% (−82.1 pts)
20172025

KRRO valuation history

Fiscal year-endToday9-year median

KRRO returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

KRRO debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

KRRO price vs earnings per share

Share price at year-endEPS (right axis)

KRRO key metrics

2017–2025
Korro Bio, Inc. key metrics by fiscal year
202520242023202220212020201920182017
Valuation
Market capitalization$75.3M$339.6M——$1.14B————
Enterprise value$43.6M$258.3M——$1.06B————
Price / sales11.8149.5——81.1————
Price / book1.52.1——8.7————
EV / sales6.8113.7——75.0————
Earnings yield−155.8%−24.6%——−1.9%————
Free cash flow yield−105.1%−23.0%——−3.2%————
Share price at fiscal year-end$8.01$38.07$47.93$192.50$256.50$1,763.00$876.50——
Per share
Revenue per share$0.68$0.25——$3.16————
Earnings per share−$12.48−$9.37——−$4.94————
Operating cash flow per share−$8.36−$6.73——−$7.22————
Free cash flow per share−$8.42−$8.74——−$8.22————
Cash per share$8.00$14.14——$29.39————
Book value per share$5.47$17.98——$29.42————
Tangible book value per share$5.47$17.98——$29.42————
Capex per share$0.06$2.01——$1.00————
Debt per share$4.63$5.02——$10.25————
Shares outstanding9.4M8.9M——4.4M————
Change in shares outstanding+5.3%————————
Returns & profitability
Return on equity (ROE)−110.7%−50.6%−229.0%—−13.6%−14.7%−31.5%——
Return on invested capital (ROIC)−139.6%−125.1%−272.1%−161.2%−87.8%————
Return on assets (ROA)−69.0%−37.3%−55.0%−44.8%−9.8%−10.9%−14.0%−59.6%−102.3%
Return on tangible assets−103.3%−36.9%−36.6%−78.7%−11.8%−10.0%−8.4%−43.0%−102.3%
Free cash flow margin————−259.7%−140.2%114.5%——
Financial health
Total debt$43.5M$44.8M$33.2M$167.0M$45.6M$46.0M$1$84.9M$46.7M
Cash & short-term investments$75.2M$126.1M$166.2M$55.9M$130.7M$220.3M$217.4M$42.2M$17.9M
Net debt−$31.7M−$81.3M−$132.9M$111.1M−$85.1M−$174.3M−$217.4M$42.7M$28.8M
Debt / equity0.850.280.20—0.350.240.00——
Debt / assets0.380.200.152.260.250.170.001.912.36
Current ratio6.908.798.876.5611.798.454.1911.388.07
Quick ratio6.908.798.876.5611.808.454.1911.388.07
Interest coverage———-500.0-46.5——-178.7-93.7
Working capital$70.4M$116.6M$153.2M$48.4M$123.3M$198.4M$168.6M$39.2M$15.7M
Invested capital$19.8M$79.1M$37.0M$12.1M$45.7M$18.1M−$50.0M−$5.5M−$885,000
Tangible asset value$51.4M$160.4M$169.9M−$99.0M$130.8M$192.5M$167.4M−$44.5M−$29.6M
Net current asset value$20.3M$65.7M$121.0M−$115.7M$80.2M$152.8M$165.5M−$46.1M−$31.5M
Graham net-net per share$1.47$6.90——$17.14————
Capital allocation
Capex / revenue8.1%788.3%——31.6%18.0%3.7%——
Capex / operating cash flow——————3.1%——
Capex / depreciation0.125.022.162.082.794.221.310.673.51
Stock-based compensation / revenue119.8%196.5%——5.7%————
R&D / revenue1,025.9%2,802.1%——169.2%99.1%63.3%——
SG&A / revenue440.5%1,345.0%——83.1%————
Efficiency
Days sales outstanding76.1136.3——6.35.76.1——
Days of inventory on hand————-13.7————
Days payables outstanding240.6577.0497.0389.1392.2776.833.5797.3683.3
Cash conversion cycle (days)-164.5-440.7——-399.6-771.1-27.4——
Receivables turnover4.802.680.000.0058.1364.6059.930.00—
Payables turnover1.520.630.730.940.930.4710.910.460.53
Asset turnover0.040.010.000.000.060.150.220.000.00
Average receivables$1.3M$848,000$224,500$296,500$242,000$572,500$483,000$161,000—
Average payables$2.8M$5.6M$4.9M$2.7M$4.1M$3.4M$1.5M$1.4M$994,000
Average inventory————−$144,000————
Intangibles / total assets0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Computed from KRRO's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

KRRO valuation and financial ratios

Korro Bio earned a return on equity of −110.7% and a return on invested capital of −139.6% in fiscal 2025. It ended the year with $43.5 million of debt and $75.2 million in cash and short-term investments, a net cash position of $31.7 million.

See the KRRO income statement, the KRRO chart for price history, or the KRRO stock overview for the latest quote and news.

KRRO key metrics FAQ

What is Korro Bio's return on equity?

Korro Bio's return on equity (ROE) was −110.7% in fiscal 2025: net income of -$117.3 million on average shareholders' equity of $105.9 million.

What is Korro Bio's ROIC?

Korro Bio's return on invested capital was −139.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does Korro Bio have?

Korro Bio had total debt of $43.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.85 and more cash than debt.

What is Korro Bio's free cash flow yield?

Korro Bio generated -$79.1 million of free cash flow in fiscal 2025, a free cash flow yield of −105.1% on its market value at year-end ($75.3 million).

What is Korro Bio's current ratio?

Korro Bio's current ratio was 6.90 at the end of fiscal 2025: current assets were 6.90 times current liabilities.

Biotechnology key metrics